4-(3'-ethyl-4'-methoxy-3-methyl-biphenyl-4-yl)-4-oxo-N-pyridin-3-ylmethyl-butyramide | 947548-05-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(3'-ethyl-4'-methoxy-3-methyl-biphenyl-4-yl)-4-oxo-N-pyridin-3-ylmethyl-butyramide
• 英文别名: 4-[4-(3-ethyl-4-methoxyphenyl)-2-methylphenyl]-4-oxo-N-(pyridin-3-ylmethyl)butanamide
• CAS: 947548-05-2
• 化学式: C₂₆H₂₈N₂O₃
• 分子量: 416.52
• InChiKey: DPCQBFMBAJQVAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  68.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(3'-ethyl-4'-methoxy-3-methyl-biphenyl-4-yl)-4-oxo-N-pyridin-3-ylmethyl-butyramide 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 以93%的产率得到4-(3'-ethyl-4'-hydroxy-3-methylbiphenyl-4-yl)-4-oxo-N-pyridin-3-ylmethylbutyramide
  参考文献：
  名称：

  Novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1: Templates for design

  摘要：

  The 17 beta-hydroxysteroid dehydrogenases (17 beta-HSDs) catalyze the interconversion between the oxidized and reduced forms of androgens and estrogens at the 17 position. The 17 beta-HSD type 1 enzyme (17 beta-HSD1) catalyzes the reduction of estrone (E1) to estradiol and is expressed in malignant breast cells. Inhibitors of this enzyme thus have potential as treatments for hormone dependent breast cancer. Syntheses and biological evaluation of novel non-steroidal inhibitors designed to mimic the E1 template are reported using information from potent steroidal inhibitors. Of the templates investigated biphenyl ethanone was promising and led to inhibitors with IC50 values in the low micromolar range. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.02.059
• 作为产物：
  描述：

  3-氨甲基吡啶 、 4-(3'-ethyl-4'-methoxy-3-methyl-biphenyl-4-yl)-4-oxo-butyric acid 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以87%的产率得到4-(3'-ethyl-4'-methoxy-3-methyl-biphenyl-4-yl)-4-oxo-N-pyridin-3-ylmethyl-butyramide
  参考文献：
  名称：

  Novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1: Templates for design

  摘要：

  The 17 beta-hydroxysteroid dehydrogenases (17 beta-HSDs) catalyze the interconversion between the oxidized and reduced forms of androgens and estrogens at the 17 position. The 17 beta-HSD type 1 enzyme (17 beta-HSD1) catalyzes the reduction of estrone (E1) to estradiol and is expressed in malignant breast cells. Inhibitors of this enzyme thus have potential as treatments for hormone dependent breast cancer. Syntheses and biological evaluation of novel non-steroidal inhibitors designed to mimic the E1 template are reported using information from potent steroidal inhibitors. Of the templates investigated biphenyl ethanone was promising and led to inhibitors with IC50 values in the low micromolar range. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.02.059

文献信息

• COMPOUND
  申请人：VICKER Nigel

  公开号：US20090186900A1

  公开（公告）日：2009-07-23

  There is provided a compound of Formula I wherein the various symbols are as defined in the description, and a method of manufacturing a medicament for use in the therapy of a condition or disease associated with 17β-hydroxysteroid dehydrogenase (17β-HSD), comprising a compound of Formula I.

  提供了一种式子为I的化合物，其中各符号的定义如说明书所述，并提供一种制造药物的方法，用于治疗与17β-羟基类固醇脱氢酶（17β-HSD）相关的疾病或病症，包括化合物I。